Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Recruiting 4Unknown 2Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Acinar Cell 1

Interventions

Gemcitabine 42130-nm albumin-bound paclitaxel 26Albumin-Bound Paclitaxel 18Irinotecan 16Oxaliplatin 14Fluorouracil 14pembrolizumab 13Nivolumab 13Magnetic Resonance Spectroscopy 11Leucovorin 11Taxes 10Specimen Handling 9Biopsy 9Cisplatin 8Capecitabine 7folfirinox 6Radiotherapy 6Carboplatin 6irinotecan sucrosofate 5durvalumab 5Ipilimumab 5Cyclophosphamide 5olaparib 4defactinib 4Surveys and Questionnaires 4Standard of Care 4Radiosurgery 4Immunoglobulin G 4Disulfides 4dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pancreatic Neoplasms × Pancreatectomy × Clear all
NCT04594772 2026-06-01

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

University of Cincinnati

Phase 2 Active not recruiting
32 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡